<DOC>
	<DOCNO>NCT00796510</DOCNO>
	<brief_summary>As sitaxsentan agent highly selective ETA ( Endothelin Type A ( receptor ) ) , significantly impact sildenafil pharmacokinetics combination promise pulmonary arterial hypertension ( PAH ) therapy two oral drug administer combination .</brief_summary>
	<brief_title>Study Providing Monotherapy ( Sitaxsentan ) And Combination Therapy ( Sitaxsentan+Sildenafil ) To Subjects With Pulmonary Arterial Hypertension ( PAH ) To Assess Long-Term Safety</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Previously enrol B1321001 least 4 week . Previously enrol B1321003 , discontinue study . Completed B1321003 study plan . Treated investigational drug ( sitaxsentan sildenafil either B1321001 B1321003 ) device receive regulatory approval within 30 day prior Baseline/Day 1 study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>endothelin receptor antagonist ( ETRA )</keyword>
	<keyword>sitaxsentan</keyword>
</DOC>